trial

The Effect of Sertindole on Sensory Gating and Cognition in Schizophrenic Patients

NCTId NCT00629252
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Terminated
Enrollment 14 (actual)
Sponsored by University of Zurich
Primary completion 2012-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Terminated
Enrollment
14 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
Single
Start
2008-02
Primary completion
2012-08
Eligibility
ALL · 18 Years · 40 Years

Interventions & indications

Drugs
SertindoleRisperidone

Sponsors

University of ZurichLead Sponsor
University Hospital of Psychiatry, Department Neuropsychopharmacology and Brain ImagingCollaborator
H. Lundbeck A/SCollaborator

Investigators

1
Franz X. Vollenweider, Prof. Dr. med.Principal Investigator

Sites

1 total
Zurich, Switzerland

Facts & assertions

4 sourced
Enrollment
14
Phase
NA
Primary Completion Date
2012-08
Status
TERMINATED
relationships
The graph out of here
drug
Sertindole
drug
Risperidone
drug
lead_sponsor
University of Zurich
company
collaborator
University Hospital of Psychiatry, Department Neuropsychopharmacology and Brain Imaging
company
H. Lundbeck A/S
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Franz X. Vollenweider, Prof. Dr. med.
person